The revenue stands at ₹439.71 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 14.50 per cent from ₹514.27 crore. This corresponds to a year-on-year *(YoY) growth of 10.47 per cent.
Operating Profit stands at ₹77.13 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 50.41 per cent from ₹155.54 crore. This corresponds to a year-on-year *(YoY) decline of 10.94 per cent.
PBDT stands at ₹78.39 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 48.42 per cent from ₹151.97 crore. This corresponds to a year-on-year *(YoY) decline of 45.59 per cent.
Profit Before Tax stands at ₹54.47 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 57.92 per cent from ₹129.43 crore. This corresponds to a year-on-year *(YoY) decline of 57.37 per cent.
Net Profit stands at ₹40.57 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 58.11 per cent from ₹96.85 crore. This represents a 60.06 per cent year-on-year *(YoY) decline for the same year.
in ₹ cr
in ₹ cr
in ₹ cr
in ₹ cr
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Neuland Labs. | 2.27% | 9.65% | 21.70% | 34.26% | 2.86% | 40.98% |
| Wockhardt | -1.82% | 12.73% | 17.97% | 14.71% | 20.71% | 26.44% |
| Piramal Pharma | -2.23% | 12.13% | 22.70% | 9.50% | -7.46% | -15.19% |
| Sai Life | 2.46% | 3.15% | 12.85% | 17.69% | 24.50% | 56.56% |
| Acutaas Chemical | -0.21% | 2.17% | 14.18% | 34.61% | 56.04% | 130.92% |
| Pfizer | 1.20% | 2.72% | -0.80% | -7.50% | -3.71% | 13.20% |
| Astrazeneca Phar | -0.54% | 5.50% | -2.62% | -6.41% | -7.04% | 4.57% |
Executive Chairman : D R Rao
Non Executive Director : Christopher M Cimarusti
Vice Chairman & Chief Executive Officer : D Sucheth Rao
Vice Chairman & Managing Director : D Saharsh Rao
Company Sec. & Compli. Officer : Sarada Bhamidipati
Independent Director : Homi Rustam Khusrokhan
Independent Director : Prasad R Menon
Independent Director : Sugata Sircar
Independent Director : Pallavi Joshi Bakhru
Additional Director : Ravi Gopinath